Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, October 2001, p. 2703-2709, Vol. 45, No. 10
Public Health Research Institute, New York,
New York 10016,1 and Parke-Davis
Research Division, Warner-Lambert Company, Ann Arbor, Michigan
481052
Received 4 December 2000/Returned for modification 10 January
2001/Accepted 6 July 2001
The increasing prevalence of antibiotic resistance among bacterial
pathogens prompted a microbiological study of fluoroquinolone structure-activity relationships with resistant mutants. Bacteriostatic and bactericidal activities for 12 fluoroquinolones were examined with
a gyrase mutant of Mycobacterium smegmatis and a
gyrase-topoisomerase IV double mutant of Staphylococcus
aureus. For both organisms C-8 halogen and C-8 methoxy
groups enhanced activity. The MIC at which 99% of the isolates tested
were inhibited (MIC99) was reduced three- to fivefold for
the M. smegmatis mutant and seven- to eightfold for the
S. aureus mutant by C-8 bromine, chlorine, and methoxy
groups. With both organisms a smaller reduction in the
MIC99 (two- to threefold) was associated with a C-8
fluorine moiety. In most comparisons with M. smegmatis the
response to a C-8 substituent was similar (within twofold) for
wild-type and mutant cells. In contrast, mutant S. aureus
was affected more than the wild type by the addition of a C-8
substituent. C-8 halogen and methoxy groups also improved the ability
to kill the two mutants and the respective wild-type cells when
measured with various fluoroquinolone concentrations during an
incubation period equivalent to four to five doubling times.
Collectively these data help define a group of fluoroquinolones that
can serve (i) as a base for structure refinement and (ii) as test
compounds for slowing the development of fluoroquinolone resistance
during infection of vertebrate hosts.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.10.2703-2709.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Enhancement of Fluoroquinolone Activity by
C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance
Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase
IV Double Mutant of Staphylococcus aureus
*
Corresponding author. Mailing address: Public Health
Research Institute, 455 First Ave., New York, NY 10016. Phone: (212) 578-0830. Fax: (212) 578-0804. E-mail:drlica{at}phri.nyu.edu.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |